The loss of CB1R is the primary pathogenic event in HD, and pharmacological strategies that promote CB1R and CB2R signaling may lead to therapeutic benefits, the extent of which likely depends on the extent of the disease [83]. This evidence concerns the gene CNR1 and Huntington disease.